全文获取类型
收费全文 | 409篇 |
免费 | 44篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 4篇 |
妇产科学 | 19篇 |
基础医学 | 37篇 |
口腔科学 | 1篇 |
临床医学 | 51篇 |
内科学 | 124篇 |
皮肤病学 | 1篇 |
神经病学 | 52篇 |
特种医学 | 18篇 |
外科学 | 61篇 |
综合类 | 6篇 |
预防医学 | 9篇 |
眼科学 | 2篇 |
药学 | 12篇 |
肿瘤学 | 50篇 |
出版年
2023年 | 8篇 |
2022年 | 1篇 |
2021年 | 21篇 |
2020年 | 10篇 |
2019年 | 19篇 |
2018年 | 21篇 |
2017年 | 23篇 |
2016年 | 12篇 |
2015年 | 7篇 |
2014年 | 23篇 |
2013年 | 18篇 |
2012年 | 50篇 |
2011年 | 46篇 |
2010年 | 20篇 |
2009年 | 14篇 |
2008年 | 23篇 |
2007年 | 26篇 |
2006年 | 16篇 |
2005年 | 21篇 |
2004年 | 24篇 |
2003年 | 18篇 |
2002年 | 14篇 |
2001年 | 4篇 |
2000年 | 1篇 |
1999年 | 4篇 |
1996年 | 1篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1987年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有453条查询结果,搜索用时 343 毫秒
1.
2.
3.
G. Chadi A. M?er L. Rosen A. M. Janson L. A. Agnati M. Goldstein S.-O. ?gren R. F. Pettersson K. Fuxe 《Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale》1993,97(1):145-158
Basic fibroblast growth factor (bFGF, FGF-2) is a trophic factor for neurons and astrocytes and has recently been demonstrated in the vast majority of dopamine (DA) neurons of the ventral midbrain of the rat. Potential neuroprotective actions of FGF-2 in the l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) model have also been reported. The actions of the FGF-2 have now been further analyzed in a combined morphological and behavioural analysis in the MPTP model of the adult black mouse, using a continuous human recombinant FGF-2 (hrFGF-2) intraventricular (i.v.t.) administration in a heparin-containing (10 IU heparin/ml) mock cerebrospinal fluid (CSF) solution. Tyrosine hydroxylase (TH) immunocytochemistry in combination with computer assisted microdensitometry demonstrated a counteraction of the MPTP-induced disappearance of neostriatal TH-immunoreactive (ir) nerve terminals following the FGF-2 treatment. Unbiased estimates of the total number of nigral TH ir neurons, using stereological methods involving the optical disector (Olympus), showed that the MPTP-induced reduction in the number of nigral TH ir nerve cell bodies counterstained with cresyl violet (CV; by 56%) was partially counteracted by the FGF-2 treatment (by 26%). The behavioral analysis demonstrated an almost full recovery of the MPTP-induced reduction of the locomotor activity after FGF-2 treatment. This action was maintained also 1 week after cessation of treatment. The hrFGF-2 produced an astroglial reaction as determined in the lateral neostriatum and in the substantia nigra (SN) far from the site of the infusion, indicating that the growth factor may have reached these regions by diffusion to activate the astroglia. Immunocytochemistry revealed FGF-2 immunoreactivity (IR) in the nuclei of the astroglia cell population in the dorsomedial striatum and the microdensitometric and morphometric evaluation demonstrated an increase in the number, but not in the intensity, of these profiles on the cannulated side, suggesting the possibility that hrFGF-2 stimulates FGF-2 synthesis in astroglial cells with low endogenous FGF-2 IR. These results indicate that hrFGF-2, directly and/or indirectly via astroglia, upon i.v.t. infusion exerts trophic effects on the nigrostriatal DA system and may increase survival of nigrostriatal DA nerve cells exposed to the MPTP neurotoxin. 相似文献
4.
Michael J. Zobel Donna Nowicki Gabriel Gomez Jessica Lee Lori Howell Joseph Miller Chadi Zeinati Dean M. Anselmo 《Journal of pediatric surgery》2021,56(5):1062-1067
Background/PurposeCervicofacial lymphatic malformations (CFLM) are rare, potentially life-threatening vascular anomalies, yet reports on multidisciplinary treatment strategies are lacking. We evaluated outcomes for CFLMs following sclerotherapy, surgical resection, and/or medical management.MethodsWe identified children with a CFLM at a vascular anomalies center from 2004 to 2019. Exclusion criteria: retro-orbital malformations, untreated malformations, patients without follow-up. Primary clinical outcome was contour improvement, with significance defined as LM volume reduction of > 50% by cross-sectional imaging.ResultsSixty-three children met inclusion criteria: 35 with macrocystic CFLMs, six with microcystic CFLMs, and 22 with mixed-type malformations. Mean post-intervention follow-up was 27.5 months. Fifty-eight patients underwent sclerotherapy (median: two treatments). Doxycycline and/or bleomycin were used in 95% of patients. After sclerotherapy, 97% of macrocystic CFLMs improved significantly compared to 82% of mixed and 67% of microcystic lesions. Sixteen children underwent surgical resection with 75% significantly improving; two additional patients were successfully treated with sclerotherapy after debulking surgery. Six children received sirolimus for microcystic disease, of which 33% significantly improved.ConclusionSclerotherapy is very effective for macrocystic components of CFLMs, albeit less so for microcystic disease. Microcystic CFLMs frequently require surgical resection. Sirolimus is a helpful therapeutic adjunct, particularly for microcystic lesions, but more study is needed.Level of EvidenceLevel II, prognosis study 相似文献
5.
Frequency,risk factors,and outcomes of central nervous system relapse in lymphoma patients treated with dose‐adjusted EPOCH plus rituximab 下载免费PDF全文
6.
Purpose of Review
Chronic sinus and upper airway disease in children is a common health problem encountered every day. Its pathophysiology is complicated which leads to different treatment options and approaches. We seek to review the current literature and evidence to surgical treatments.Recent Findings
Medical treatment with antibiotics and topical nasal sprays continues to be the first-line treatment. Surgical interventions include adenoidectomy, balloon catheter sinuplasty (BCS), and endoscopic sinus surgery (ESS). Each modality has proven to be safe; however, its effectiveness is widely variable.Summary
More research with higher level of evidence is needed to help in choosing the right surgical treatment with optimal benefit.7.
8.
9.
10.